Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease

Lei Wang, Jun Yang, Lei Guo, Dale Uyeminami, Hua Dong, Bruce D. Hammock, Kent E Pinkerton

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Tobacco smoke-induced chronic obstructive pulmonary disease (COPD) is a prolonged inflammatory condition of the lungs characterized by progressive and largely irreversible airflow limitation attributable to a number of pathologic mechanisms, including bronchitis, bronchiolitis, emphysema, mucus plugging, pulmonary hypertension, and small-airway obstruction. Soluble epoxide hydrolase inhibitors (sEHIs) demonstrated anti-inflammatory properties in a rat model after acute exposure to tobacco smoke. We compared the efficacy of sEHI t-TUCB (trans-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]- cyclohexyloxy}-benzoic acid) and the phosphodiesterase-4 (PDE4) inhibitor Rolipram (Biomol International, Enzo Life Sciences, Farmingdale, NY) to reduce lung injury and inflammation after subacute exposure to tobacco smoke over a period of 4 weeks. Pulmonary physiology, bronchoalveolar lavage, cytokine production, and histopathology were analyzed to determine the efficacy of sEHI and Rolipramto ameliorate tobacco smoke - induced inflammation andinjury in the spontaneously hypertensive rat. Both t-TUCB and Rolipram inhibited neutrophil elevation in bronchoalveolar lavage. sEHI t-TUCB suppressed IFN-γ, while improving lung function by reducing tobacco smoke - induced total respiratory resistance and tissue damping (small-airway and peripheral tissue resistance). Increases in tobacco smoke - induced alveolar airspace size were attenuated by t-TUCB. Rolipram inhibited the production of airway mucus. Both t-TUCB and Rolipram inhibited vascular remodeling - related growth factor. These findings suggest that sEHI t-TUCB has therapeutic potential for treating COPD by improving lung function and attenuating the lung inflammation and emphysematous changes caused by tobacco smoke. To the best of our knowledge, this is the first report to demonstrate that sEHI exerts significant protective effects after repeated, subacute tobacco smoke - induced lung injury in a rat model of COPD.

Original languageEnglish (US)
Pages (from-to)614-622
Number of pages9
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Issue number5
StatePublished - May 2012


  • Airway obstruction
  • Anti-inflammatory agents
  • Experimental animal models

ASJC Scopus subject areas

  • Cell Biology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Clinical Biochemistry


Dive into the research topics of 'Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this